View Older Stories View More Recent Stories
-
Oppenheimer Reiterates Capricor Therapeutics (CAPR) at Outperform, 'like the risk-reward'
-
Capricor Therapeutics (CAPR) Falls 26% Following FDA Briefing Docs Post
-
Capricor Therapeutics (CAPR) Reiterated at Overweight by Cantor Fitzgerald
-
Capricor Therapeutics (CAPR) Reiterates Overweight Rating Ahead of Upcoming PDUFA
-
Capricor Therapeutics (CAPR) 4500 contracts of August 30 calls and 2900 contracts of August 20 puts trade
-
B.Riley Reiterates Buy Rating on Capricor Therapeutics (CAPR)
-
Capricor Therapeutics (CAPR) Misses Q1 EPS by 7c
-
Capricor sues NS Pharma over Duchenne therapy distribution deal
-
Capricor Therapeutics (CAPR) Reiterated at Overweight by Cantor Fitzgerald After Q4 Result
-
Capricor Therapeutics (CAPR) Misses Q4 EPS by 11c
-
Capricor reports positive HOPE-3 trial results for Duchenne therapy
-
Jones Trading Reiterates Buy Rating on Capricor Therapeutics (CAPR) as FDA review resumed
-
H.C. Wainwright Reiterates Buy Rating on Capricor Therapeutics (CAPR)
-
FDA sets new PDUFA date for Capricor's Deramiocel therapy
-
Truist on Head of CBER at FDA Exit: 'we anticipate a positive stock reaction for IRON CAPT RGNX QURE'
-
Oppenheimer Reiterates Outperform Rating on Capricor Therapeutics (CAPR)
-
CAPR receives FDA request for clinical study report on Deramiocel
-
Capricor Therapeutics (CAPR) Reiterated at Overweight by Cantor Fitzgerald
-
Capricor Therapeutics (CAPR) Reiterated at Overweight by Cantor Fitzgerald
-
Piper Sandler Highlights Top Picks in the Biopharma 2026 Preview Note
-
Biotechnology: Here are Piper Sandler's Top Picks and Focus Names for 2026
-
Piper Sandler: 'We Are Naming Capricor Therapeutics (CAPR) As a 2026 Top Pick'
-
Capricor Therapeutics (CAPR) PT Raised to $45 at Piper Sandler
-
Capricor Therapeutics (CAPR) PT Raised to $54 at Oppenheimer
-
Capricor Therapeutics (CAPR) call put ratio 1 call to 1.6 puts as share price up
-
Capricor Therapeutics (CAPR) PT Raised to $51 at Jones Trading
-
Capricor Therapeutics (CAPR) PT Raised to $60 at H.C. Wainwright
-
B.Riley Reiterates Capricor (CAPR) at Buy, 'believe Deramiocel peak sales could likely exceed $1B'
-
Capricor Therapeutics (CAPR) Halted, News Pending
-
Increasing unusual put option volume: CAPR ABTC BRR WY HUBS PALL SM IOT
-
Increasing unusual put option volume: EWC DJX SLG CAPR STNG HUBS ANF URBN DLO WGS KVYO
-
Increasing unusual put option volume: SLG CAPR DLO WGS TSCO
-
Capricor Therapeutics (CAPR) Mentioned as Short by Shkreli
-
Capricor presents scalable exosome loading framework at AAEV conference
-
Capricor Therapeutics (CAPR) call put ratio 1 call to 5.6 puts with a focus on November 2.5 puts
-
Capricor Therapeutics (CAPR) Reports In-Line Q3 EPS, offers outlook
-
Capricor Therapeutics publishes study on Deramiocel mechanism
-
Options with decreasing option implied volatility: CAPR FDX WBD ACN MU LEN
-
Capricor receives FDA clarity on Deramiocel approval path for DMD
-
Jones Trading Reiterates Buy Rating on Capricor Therapeutics (CAPR)
-
H.C. Wainwright Reiterates Buy Rating on Capricor Therapeutics (CAPR)
-
Capricor responds to FDA posting of Deramiocel rejection letter
-
H.C. Wainwright Reiterates Buy Rating on Capricor Therapeutics (CAPR)
-
Capricor Therapeutics (CAPR) Misses Q2 EPS by 9c
-
Capricor schedules FDA meeting on Deramiocel regulatory path
-
Oppenheimer Reiterates Outperform Rating on Capricor Therapeutics (CAPR)
-
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics
-
CAPR ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Capricor Therapeutics, Inc. Investors
-
Capricor Therapeutics (CAPR) PT Lowered to $24 at H.C. Wainwright
